The Effects of Postmenopausal Hormone Use on Cataract: A Meta-Analysis

Kairan Lai1, Jiantao Cui1, Shuang Ni1, Yidong Zhang1, Jiliang He2, Ke Yao1,3*

1 Eye Center, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, 2 Institutes of Environmental Medicine, School of Medicine, Zhejiang University, Hangzhou, China, 3 Zhejiang Provincial Key Laboratory of Ophthalmology, Hangzhou, China

Abstract

Background: Cataract is the leading cause of blindness worldwide. Many observational studies assessed the relationship between postmenopausal hormone replacement therapy (HRT) and risk of cataract development, but the reported results were controversial. The aim of present meta-analysis was to evaluate the association of postmenopausal hormone replacement therapy with risk of cataract development.

Methods: The eligible observational studies, including cross-sectional, case–control and cohort studies, were identified by searching PubMed and Embase during March of 2013. Either a fixed- or a random-effects model was used to calculate the pooled odds ratio (OR) with its 95% confidence interval (95%CI). Subgroup analysis on cataract types was performed.

Results: A total of four cohort and five case-control or cross-sectional studies were finally included into this meta-analysis. Overall, a significant decreased risk of developing any type of cataract was found in ever HRT group as compared with non-HRT group among cohort studies (OR 0.83; 95%CI: 0.71,0.97) and case-control or cross-sectional studies (OR 0.74; 95%CI: 0.59,0.93). Subgroup analysis on cataract types determined that the significantly decreased risk of nuclear cataract in current HRT group (OR 0.72; 95%CI: 0.61,0.85) and also a critically reduced risk of nuclear cataract in ever HRT group (OR 0.80; 95% CI: 0.64,1.01) were found among case-control or cross-sectional studies, as compared with non-HRT group. No association of HRT with risk of cortical and posterior subcapsular cataract was observed.

Conclusions: The results of present meta-analysis indicate that postmenopausal hormone use may play a protective role in cataract development.

Introduction

Cataract is the major cause of visual impairment and blindness in older adults in the world [1]. As the world’s population is aging, the prevalence of cataract is also increasing. The cataract is a significant global problem and challenge. Data from Australia and the Barbados eye studies indicated that female gender is one of the risk factors for cortical and nuclear cataract [2,3]. A number of previous epidemiologic studies have also shown an increased prevalence of cataract in women compared with men [4–7]. It was suggested that the estrogen may play a role in the cataract formation and progression.

Hormone replacement therapy is widely used in the treatment of menopausal symptoms [8], although recent studies have shown the consistent evidence of an increased risk for breast cancer and endometrial cancer in females with long-term use of hormone replacement therapy [9–11]. Evidence from laboratory studies has suggested that estrogen may protect against the development of cataract [12,13]. However, the results from epidemiological studies indicated that the association of HRT with risk of cataract was inconclusive. Some studies have demonstrated that HRT was associated with a decreased prevalence of lens opacities [14–18]. On the contrary, several studies reported no protective effect of HRT on cataract development [19–21]. The individual
studies may be restricted in terms of the sample size. Therefore, in present investigation the methods of meta-analysis of the published observational studies were utilized to analyze the relationship between HRT and the prevalence of cataract, in order to provide high-quality evidence for potential therapeutic options.

Materials and Methods

1: Search strategy and Selection of the Papers
The meta-analysis was performed, according to the PRISMA in systematic review and meta-analysis [22]. PubMed and Embase have been searched for original papers concerning the effects of postmenopausal hormone use on cataract until March 10, 2013. The search strategy was composed of cataract (e.g. cataract, lens opacity and crystalline opacity), hormone replacement (e.g. hormone replacement therapy, estrogen replacement therapy and estrogens) and human studies. Furthermore, the reference lists of the selected relevant papers were screened by hand for potentially relevant new papers. Cross-sectional, case–control or cohort studies incorporated in the present meta-analysis should meet the following inclusion criteria: (1) original papers which reported independent data; (2) the studies which considered the postmenopausal females as an independent study population for analysis; (3) the studies which estimated the effects of HRT on the risk of cataract with odds ratio (OR) or relative ratio (RR) and its 95% confidence interval (CI). Papers were excluded on the basis of following criteria: (1) Non-original paper (e.g. review, letter or comment etc.); (2) Non-human investigation (e.g. animal study or vitro study); (3) Anti-estrogen medication (e.g. tamoxifen) for treatment of other diseases; (4) Double publication. In case the published papers used the same database to assess the relationship between exposure and outcome, only the most recent or informative one was included.

2: Data Extraction and Quality Assessment
The following data were extracted independently by two authors (K. Lai and J. Cui) from each study: first author's name, year of publication, country, study period, study design, sample size, age, cataract definitions and grading, HRT status, adjusted variables, and OR/RR values with 95% CI. The results were compared, and conflicting evaluations were discussed among all authors and resolved with consensus. HRT status was divided into current HRT, past HRT and ever HRT. Current HRT had a history of HRT with HRT prescription used currently. Past HRT had a history of HRT with no current HRT prescription. Ever HRT had a history of HRT regardless of current HRT use. As the outcome of interest, cataract is a disease presented with opacity in the lens or capsule of the eye, which leads to a decreased vision. Cataract mainly includes three subtypes, i.e. cortical cataract, nuclear cataract and posterior subcapsular cataract (PSC). The patients were diagnosed through examination at a slit lamp by ophthalmologists according to grading systems.

Our primary analysis compared the risk of cataract between ever HRT users and never HRT users. Several studies did not provide an overall OR/RR for ever HRT users, but showed the separate adjusted odds ratio of different duration of postmenopausal hormone use or HRT status (past and current). And some studies did not report an OR/RR for any type of cataract, but for subtypes (cortical cataract, nuclear cataract and posterior subcapsular cataract). For reason given above, Jan Hamling’s method [23] was used to estimate the adjusted overall OR/RR on the basis of Greenland and Longnecker’s effective numbers approach. In addition, the relationship between HRT status and the subtypes of cataract was estimated. Quality assessment for the included studies in this meta-analysis was performed using the Newcastle Ottawa scale (NOS) [24]. The studies that met 5 or more of the NOS criteria were considered as high quality.

3: Statistical Methods
OR with its 95% CI was used as a common measure for the association of HRT with risk of cataract across studies. The RR was directly considered as OR. Cochran’s Q-statistic and I² score [25] were utilized to assess possible heterogeneity among the individual studies. When the P-value for heterogeneity is < 0.10 or I² is > 50%, substantial heterogeneity was detected. The fixed-effects model (the inverse variance method [26]) was used when no heterogeneity was observed throughout included studies. Otherwise, the random-effects model (DerSimonian and Laird method [27]) was used.

Subgroup analysis was conducted regarding the association of HRT status (past and current use) with risk of cataract subtypes (cortical cataract, nuclear cataract and posterior subcapsular cataract), respectively.

Potential publication bias was assessed by the Egger’s linear regression test [28] and the Begg’s rank correlation test [29]. The statistical software was Stata version 11.0 (Stata Corporation, College Station, TX), and the significance level was set to P < 0.05 or P<0.01.

Results

1: Characteristics of studies
The search strategy retrieved 96 unique citations from MEDLINE (PubMed) and EMBASE databases. Of these, 76 were excluded after reviewing titles and abstracts, 20 articles for full-text review were left. In this review, 11 articles were excluded for following reasons: one article was a lens transmittance study [30], one article provided Hazard ratio (HR) instead of OR/RR [31], two articles did not provide OR and its 95% CI or sufficient information to estimate a summary OR and its 95% CI [21,32], one article identified cataract subtypes as water clefts and retrodots [33], in one article the cataract extraction served as the measure of outcome [34], and the data used in five articles were the same as other studies [15,17,35–37]. Finally, four cohort studies [18,38–40], two case-control studies [14,41] and three cross-sectional studies [3,16,19] were included in our meta-analysis. Figure 1 shows a flow of search results.

The characteristics of the included studies were presented in table 1. Among the 9 included studies, four, two, two and one studies were conducted in USA, Europe, Australia and Asia, respectively. Seven studies were the population-based studies,
one was the hospital-based study and one was a selected group-based study. Different standardized criteria were used for diagnosis of cataract in some studies, while the cases in other studies were diagnosed medically by ophthalmologist or medical record review. According to NOS system, 9 included studies were considered as high quality.

2: Cohort studies

In four [18,38–40], two [38,40] and two [38,40] studies the analysis of ever, past, current postmenopausal hormone use and risk of any type of cataract was performed, respectively. Figure 2 shows there was a statistically significant decrease for the association of ever HRT with risk of any type of cataract in a fixed-effects model (OR 0.83; 95% CI: 0.71, 0.97; \( P<0.05 \)). But there was no significant difference for developing any type of cataract.
### Table 1. Characteristics of 9 studies included into this meta-analysis.

| Reference     | Country | Study design                  | Sample size (females) | Age      | Cataract types            | Case criteria                        | HRT Status           | Adjusted variables                                                                 |
|---------------|---------|--------------------------------|-----------------------|----------|---------------------------|--------------------------------------|----------------------|--------------------------------------------------------------------------------------|
| Klein 2000    | USA     | population-based cohort       | 1132                  | 65 (mean)| Any type                  | Wisconsin Cataract Grading System     | Duration of HRT | Age                                                                                 |
| Worzala 2001  | USA     | population-based cohort       | 529                   | 66-93    | Any type, nuclear, cortical, PSC | Standardized Grading System by Taylor and West | Duration of estrogen use | Age, type of menopause, age at menarche, diabetes, BMI, hypertension and cigarette smoking |
| Weintraub 2002| USA     | selected group-based cohort   | 480                   | 63 (mean)| Any type, nuclear, cortical | LOCS III                            | Ever, past, current | Age, pack years of smoking, average vitamin C intake and BMI                           |
| Kanthan 2010  | Australia| population-based cohort       | 1159                  | 59+      | Nuclear, cortical, PSC    | Wisconsin Cataract Grading System     | Past, Current       | Age, smoking, use of oral or inhaled steroids, socioeconomic status, myopia, hypertension and diabetes. |
| Aina 2006     | UK      | population-based case-control | 20000                 | 81 (mean)| Any type                  | None shown                           | Past, Current       | Age, consultation rate                                                               |
| Noran 2007    | Malaysia| hospital-based case-control   | 242                   | 63.8 (mean)| Any type                 | None shown                           | Duration of estrogen use | Age, ethnic, education, smoking status, alcohol consumption, family history of cataract, aspirin and steroids intake, diabetes mellitus, hypertension, and other reproductive factors |
| McCarty 1999  | Australia| population-based cross-sectional| 2850                  | 61 (mean)| Nuclear, cortical         | Wilmer Cataract Grading System       | Ever                 | Age, education occupation, hypertension, diabetes, BMI, arthritis, smoking history, alcohol use, et al. |
| Freeman 2001  | USA     | population-based cross-sectional| 1239                  | 65-84    | Any type, Nuclear, cortical, PSC | Wilmer Cataract Grading System       | Past, Current       | Age, race, hypertension, smoking, alcohol consumption, age at menopause, age at menarche, diabetes, steroid use, hysterectomy, BMI, education, number of births, use of birth control pills, et al. |
| Defay 2003    | France  | population-based cross-sectional| 1410                  | 60-93    | Any type, nuclear, cortical, PSC | LOCS III                            | Past, Current       | Age, education, brown iris, smoking, diabetes mellitus, corticosteroid therapy, asthma or chronic bronchitis, plasma retinol, plasma glutathione peroxidase, erythrocyte superoxide dismutase activity and sunlight exposure |

HRT: hormone replacement therapy; PSC: posterior capsular cataract; LOCS III: Lens Opacities Classification System III; BMI: body mass index.
doi: 10.1371/journal.pone.0078647.t001
of cataract in past HRT group (OR 1.00; 95% CI: 0.76, 1.30),
current HRT group (OR 0.87; 95% CI: 0.68, 1.12), as
compared with non-HRT group. There was no substantial
heterogeneity among the included studies (ever HRT group:
P=0.396, I²=0.0%; past HRT group: P=0.836, I²=0.0%; current
HRT group: P=0.678, I²=0.0%). No publication bias was found
among the four included studies (Begg, P=0.308; Egger,
P=0.188).

Three [18,38,40], two [38,40] and two [38,40] studies were
included in the analysis of the risk of nuclear cataract in past,
current and ever HRT groups, respectively. There was no
significant difference for developing nuclear cataract in past
HRT group (OR 1.20; 95% CI: 0.87, 1.67), current HRT group
(OR 0.80; 95% CI: 0.59, 1.07) and ever HRT group (OR 0.86,
95% CI: 0.69, 1.07), as compared with non-HRT group. There
was no substantial heterogeneity among the included studies
(ever HRT group: P=0.233, I²=31.4%; past HRT group: P=0.804,
I²=0.0%; current HRT group: P=0.204, I²=38.0%). Publication bias was found among the four included studies by
the Egger’s linear regression test (P=0.003), but not by the
Begg’s rank correlation test (P=0.296).

Three [18,38,40], two [38,40] and two [38,40] studies were
included in the analysis of the risk of cortical cataract in past,
current and ever HRT groups, respectively. There was no
significant difference for developing cortical cataract in past
HRT group (OR 0.91; 95% CI: 0.67, 1.23), current HRT group
(OR 0.90; 95% CI: 0.68, 1.19) and ever HRT group (OR 0.92;
95% CI: 0.75, 1.13), as compared with non-HRT group. There
was no substantial heterogeneity among the included studies
(ever HRT group: P=0.539, I²=0.0%; past HRT group: P=0.319,
I²=0.0%; current HRT group: P=0.412, I²=0.0%). No publication bias was found among this subgroup (Begg, P=1.000; Egger, 
P=0.993).

Two [18,40] studies were included in the analysis of the association between risk of post subcapsular cataract and ever
HRT. Substantial heterogeneity was observed (P=0.090, 
I²=65.2%). The summary OR was 0.67 (95% CI: 0.35, 1.29)
with a random-effects model.

3: Case-control and cross-sectional studies

Four [14,16,19,41] studies were included in the analysis of
ever postmenopausal hormone use and risk of any type of
cataract. Figure 3 shows a statistically significant decrease for
the association of ever HRT with risk of any type of cataract in a
random-effects model (OR 0.74; 95% CI: 0.59, 0.93; P<0.05).
Substantial heterogeneity was observed (P=0.079, I²=55.8%).
Further scrutiny indicated that the heterogeneity shifted from
P=0.079 to P=0.582 by Q test and I² score shifted from 55.8%
to 0.0% when the only study conducted in Asia with a small
sample size (Noran, et al.) was excluded (OR 0.80; 95% CI: 
0.71,0.90; P<0.01; a fixed-effects model). No significant
publication bias was found among the four included studies
(Begg, P=0.308; Egger, P=0.267).

Three [14,16,19] studies were included in the separate
analysis of the association of past or current HRT with risk of

Figure 2. The association of HRT with risk of any type of cataract in cohort studies.

doi: 10.1371/journal.pone.0078647.g002
any type of cataract. There was a significantly decreased risk of developing any type of cataract in current HRT group (OR 0.72, 95% CI: 0.61, 0.85; P<0.01), but not in past HRT group (OR 0.91, 95% CI: 0.78, 1.06), as compared with non-HRT group (Figure 4). There was no substantial heterogeneity among the included studies (past HRT group: P=0.968, I²=0% and current HRT group: P=0.117, I²=43.3%).

Three [3,16,19], two [16,19] and two [16,19] studies were included in the analysis of the risk of nuclear cataract in past, current and ever HRT groups, respectively. There was a
significantly decreased risk of developing nuclear cataract in current HRT group (OR 0.50; 95% CI: 0.33, 0.76; \( P < 0.01 \)) and a critically decreased risk in ever HRT group (OR 0.80; 95% CI: 0.64, 1.01; \( P = 0.059 \)), but not in past HRT group (OR 0.89; 95% CI: 0.65, 1.22), as compared with non-HRT group (Figure 5). There was no substantial heterogeneity among the included studies (past HRT group: \( P = 0.872 \), \( I^2 = 0\% \); current HRT group: \( P = 0.840 \), \( I^2 = 0\% \); past HRT group: \( P = 0.284 \), \( I^2 = 20.5\% \)). No significant publication bias was found among the three included studies (Begg, \( P = 1.000 \); Egger, \( P = 0.670 \)).

The studies included in the analysis of the risk of cortical cataract were the same as those in the analysis of nuclear cataract for each group. There was no significant difference for developing cortical cataract in past HRT group (OR 1.02; 95% CI: 0.71, 1.47), current HRT group (OR 0.67; 95% CI: 0.37, 1.22) and ever HRT group (OR 0.93; 95% CI: 0.72, 1.18), as compared with non-HRT group. No substantial heterogeneity was detected among the included studies (ever HRT group: \( P = 0.429 \), \( I^2 = 0\% \); past HRT group: \( P = 0.666 \), \( I^2 = 0\% \); current HRT group: \( P = 0.783 \), \( I^2 = 0\% \)). No publication bias was found among this subgroup (Begg, \( P = 1.000 \); Egger, \( P = 0.054 \)).

### Discussion

The results of present meta-analysis showed that postmenopausal hormone use was associated with a decreased risk of cataract without regard to the cataract type for ever HRT users in cohort and case-control or cross-sectional studies. Also the same association of current HRT with nuclear cataract was found in case-control or cross-sectional studies. However, no association of ever HRT with risk of cortical cataract and PSC was found in our meta-analysis.

Considering the different status of HRT use, the current HRT users had a decreased risk of developing any type of cataract, nuclear cataract and cortical cataract, but neither any type of cataract nor subtypes were correlated with the past HRT. Because of the limited studies included in the subgroup analysis, the results should be interpreted with caution.

Our findings are similar to a lens transmittance study conducted by Castillo et al. [30], in which 19 postmenopausal women with estrogen for more than 4 years (group 1), 20 postmenopausal women without estrogen (group 2), and 23 age-matched men (group 3) were studied. Lens transmittance values in the three groups were 0.905 ± 0.03, 0.839 ± 0.08, and 0.841 ± 0.08, respectively. There was a significant difference between group 1 and the other two groups and it was suggested that there was a protective effect of estrogen on the lenses of postmenopausal women. However, Uncu et al. reported a dissimilar finding that HRT did not affect lens opacity after treatment for 12 months[21].

Our meta-analysis indicated that current HRT users had a slightly lower risk of cataract as compared with past HRT users. Each article, which evaluated current and past HRT use separately, reported the same tendency [14,16,19,38,40]. One possible reason is that the exposure time and concentrations of
estrogen in current HRT users may be higher than those in past HRT users. It was reported in Framingham study [18] that the increasing duration of postmenopausal estrogen use was strongly associated with a decreased prevalence of any type of cataract and nuclear cataract, and borderline association of the increasing duration of HRT with decreased risk of posterior subcapsular cataract was found. In Salisbury eye evaluation project [16], in the subjects with HRT for more than 3 years, the odds ratios were 0.6, 0.6 and 0.3 for nuclear, cortical and posterior subcapsular cataract, respectively. But in the subjects with HRT for less than 3 years, the odds ratios were 0.7, 1.4 and 0.4 for nuclear, cortical and posterior subcapsular cataract, respectively. A relative lower OR for a longer duration of HRT was also found in the POLA study [19] and a Malaysian study [41]. Also Malaysian study indicated that females exposed to endogenous estrogen for less than 32 years had a significantly higher risk of developing cataract, as compared with those exposed to endogenous estrogen for more than 32 years [41]. A similar but not significant tendency was found by the Blue Mountains Eye Study [40], the Beaver Dam Eye Study [39], and the Aravind Comprehensive Eye Survey [20].

The present meta-analysis showed that the association of HRT with risk of nuclear cataract was significantly stronger than the association of HRT with cortical and post subcapsular cataract. The human lens grows continuously throughout life by the addition of fiber cells, and the lens core faces a longer interaction with estrogen receptors (ERs). ER has been identified to be presented in the eye and is capable of inducing opacities in cultured rat lenses. Lenses from ovariectomized female rats showed the increased sensitivity to the damaging effects induced by TGF-β, and the estrogen replacement in vivo, or exposure to estrogen in vitro, could restore the resistance. The maintaining effect of estrogen on the normal function of cell membrane has also been considered to be a possible molecular mechanism [47].

Several limitations of present meta-analysis should be considered. First of all, the postmenopausal hormone replacement therapy was estimated by the self-report questionnaires in most studies, resulting in misclassification of exposure status and a existing recall and selection bias, confounding the association of HRT use with risk of cataract. And the definitions of HRT use (including the regimen, dosage and duration) were various in each study and contributed to an increase of heterogeneity. Secondly, the assessment of cataract or its subtypes varied between studies and a few studies even did not exhibit the case criteria and grading system. Thirdly, the adjusted factors in each study were different and some confounding factors which might account for the association of HRT with risk of cataract were not adjusted in some of the included studies. Although all studies were considered as high quality according to the corresponding quality assessment, the different study designs would inevitably lead to the increased inter-study heterogeneity. In addition, we did not try to contact the authors for original information which was not available in published form, and the estimates by statistical methodology might be a little different from the actual data. Because of the limited studies, the results should be interpreted with caution, and an update meta-analysis should be conducted with inclusion of newly published studies.

Our study found that postmenopausal hormone use had a protective effect on cataract development. Further studies are needed to confirm these findings and make a better understanding of the biological mechanisms. Due to the reported effect of hormone replacement therapy on breast cancer, endometrial cancer, cardiovascular disease, osteoporosis and diseases of other systems, medical professionals should take all potential benefits and risks into account when considering HRT.

Supporting Information

Checklist S1. PRISMA 2009 checklist in this meta-analysis.

(DOC)

Author Contributions

Conceived and designed the experiments: KL JH KY. Performed the experiments: KL JC SN YZ. Analyzed the data: KL JC KY. Contributed reagents/materials/analysis tools: KL JC KY. Wrote the manuscript: KL JH KY.

References
Postmenopausal Hormone Use on Cataract

1. Pascolini D, Mariotti SP (2012) Global estimates of visual impairment: 2010. Br J Ophthalmol 96: 614-618. doi:10.1136/bjo.2011-300539. PubMed: 22133988.

2. Leske MC, Wu SY, Nemecure B, Li X, Hennis A et al. (2000) Incidence and progression of lens opacities in the Barbados Eye Studies. Ophthalmology 107: 1267-1273. doi:10.1016/S0140-6736(00)01455-X. PubMed: 10889056.

3. McCarty CA, Mukesh BN, Fu CL, Taylor HR (1999) The epidemiology of cataract in Australia. Am J Ophthalmol 128: 446-465. doi:10.1016/S0002-9394(99)00218-4. PubMed: 10577586.

4. Delcourt C, Cristol JP, Tessier F, Léger CL, Michel F et al. (2000) Risk factors for cortical, nuclear, and posterior subcapsular cataracts: the POLA study. Pathologies Oculaires Liees a l'Age. Am J Epidemiol 151: 497-504. doi:10.1093/oxfordjournals.aje.a010235. PubMed: 10709718.

5. Hillier R, Spendro RD, Ederer F (1993) Epidemiologic associations with nuclear, cortical, and posterior subcapsular cataracts. Am J Epidemiol 124: 916-925. PubMed: 3776974.

6. Klein BE, Klein R, Linton KL (1992) Prevalence of age-related lens opacities in a population. The Beaver Dam Eye Study. Ophthalmology 99: 546-552. PubMed: 1984573.

7. Mitchell P, Cumming RG, Attebo K, Panchapakesan J (1997) Prevalence of cataract in Australia: the Blue Mountains eye study. Ophthalmology 104: 581-588. doi:10.1016/S0140-6736(97)03268-8. PubMed: 9111249.

8. Abraham S, Perez J, Clarkson R, Llewellyn-Jones D (1995) Australian women's perceptions of hormone replacement therapy over 10 years. Maturitas 21: 91-95. doi:10.1016/S0378-7212(94)00881-7. PubMed: 729556.

9. Beral V, Bull D, Reeves G (2005) Endometrial cancer and hormone-replacement therapy in the Million Woman Study. Lancet 365: 1543-1551. doi:10.1016/S0140-6736(05)66455-0. PubMed: 15866308.

10. Gray S (2003) Breast cancer and hormone-replacement therapy: the Million Woman Study. Lancet 362: 1332; author reply 145759314575984.

11. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C et al. (2002) Risks and benefits of estrogen plus progesterin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 289: 321-333. doi:10.1001/jama.289.3.321. PubMed: 12113977.

12. Bigsby RM, Cardenas H, Caperell-Grant A, Grubbs CJ (1999) Postmenopausal estrogen use, type of menopause, and lens opacities: effect of hormone replacement therapy on lens opacities and intraocular pressure. Gynecol Endocrinol 22: 501-505. doi:10.1080/09513590600973191. PubMed: 17071534.

13. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.

14. Cumming RG, Lee P, Weltkunst R, Ambühl M (2008) Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Stat Med 27: 954-970. doi:10.1002/sim.3013. PubMed: 17676579.

15. Crookes G, ([surname]) O’connell D, Peterson J, Welch V et al. (2012) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Health Research Institute Web site.

16. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 556-560. doi:10.1136/bmj.327.7414.557. PubMed: 12958120.

17. Wolfe B (1955) On estimating the relation between blood group and disease. Ann Hum Genet 19: 251-253. doi:10.1111/j.1469-1809.1955.tb01348.x. PubMed: 14388528.

18. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. doi:10.1136/bmj.315.7109.629. PubMed: 9310563.

19. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101. doi:10.2307/2533446. PubMed: 7766990.

20. Benitez del Castillo JM, del Rio T, Garcia-Sanchez J (1997) Effects of estrogen use on lens transmittance in postmenopausal women. Ophthalmology 104: 970-973. doi:10.1016/S0140-6736(97)90199-5. PubMed: 9166438.

21. Chang JR, Koo E, Agron E, Haukå, Clemons T et al. (2011) Risk factors associated with incident cataracts and cataract surgery in the Age-Related Eye Disease Study (AREDS): AREDS Report number 32. Ophthalmology 118: 2113-2119.

22. Pelit A, ([surname]) Pelit A, Aydin Akova Y (2007) The effect of postmenopausal hormone replacement therapy on lens opacities and intraocular pressure. Turkije Klinikleri J Med Sci 27: 811-815. PubMed: 17542127.

23. Durant JS, Frost NA, Trivella M, Sparrow JM (2006) Risk factors for cataract subtypes waterclefts and retrotunds: two case-control studies. Eye (Lond) 20: 1254-1267. doi:10.1038/sj.eye.6702087. PubMed: 16227982.

24. Lindblad BE, Häkansson N, Philipson B, Wolk A (2010) Hormone replacement therapy in relation to risk of cataract extraction: a prospective study of women. Ophthalmology 117: 424-430. doi:10.1016/j.ophtha.2009.07.046. PubMed: 20045586.

25. Klein BE (1995) Lens opacities in women in Beaver Dam, Wisconsin: is there evidence of an effect of sex hormones? Trans Am Ophthalmol Soc 93: 517-544. PubMed: 8140704.

26. Younan C, Mitchell P, Cumming RG, Panchapakesan J, Rocktachia E et al. (2002) Hormone replacement therapy, reproductive factors and the incidence of cataract and cataract surgery: the Blue Mountains Eye Study. Am J Epidemiol 155: 997-1006. doi:10.1093/aje/155.11.997. PubMed: 12034578.

27. Freeman EE, Munoz B, Schein OD, West SK (2004) Incidence and progression of lens opacities: effect of hormone replacement therapy and reproductive factors. Epidemiology 15: 451-457. doi:10.1097/01.epe.0000129517.92192.29. PubMed: 15232406.

28. Weintraub JM, Taylor A, Jacques P, Willett WC, Rosner B et al. (2002) Postmenopausal hormone use and lens opacities. Ophthalmology 9: 179-190. doi:10.1016/S0144-1869(01)01471-5. PubMed: 11386895.

29. Defay R, Pinchot J, Lacroix A, Boisserie C, Papoz L et al. (2003) Relationships between hormonal status and cataract in french postmenopausal women: the POLA study. Ann Epidemiol 13: 638-644. doi:10.1016/S1047-2797(03)00058-9. PubMed: 14732303.

30. Nirmalan PK, Katz J, Robin AL, Ramakrishnan R, Krishnasad R et al. (2004) Female reproductive factors and eye disease in a rural South Indian population: the Aravind Comprehensive Eye Survey. Invest Ophthalmol Vis Sci 45: 4273-4276. doi:10.1167/iovs.04-0285. PubMed: 15575432.

31. Uncu G, Avci R, Uncu Y, Kaymaz C, Develioglu O (2006) The effects of different hormone replacement therapy regimens on tear function, intrasaccular pressure and lens opacity. Gynecol Endocrinol 22: 501-505. doi:10.1080/09513590600973191. PubMed: 17071534.
43. Wang X, Simpkins JW, Dykens JA, Cammarata PR (2003) Oxidative damage to human lens epithelial cells in culture: estrogen protection of mitochondrial potential, ATP, and cell viability. Invest Ophthalmol Vis Sci 44: 2067-2075. doi:10.1167/iovs.02-0841. PubMed: 12714645.

44. Ogueta SB, Schwartz SD, Yamashita CK, Farber DB (1999) Estrogen receptor in the human eye: influence of gender and age on gene expression. Invest Ophthalmol Vis Sci 40: 1906-1911. PubMed: 10440242.

45. Davis VL, Chan CC, Schoen TJ, Couse JF, Chader GJ et al. (2002) An estrogen receptor repressor induces cataract formation in transgenic mice. Proc Natl Acad Sci U S A 99: 9427-9432. doi:10.1073/pnas.132247999. PubMed: 12082175.

46. Hales AM, Schulz MW, Chamberlain CG, McAvoy JW (1994) TGF-beta 1 induces lens cells to accumulate alpha-smooth muscle actin, a marker for subcapsular cataracts. Curr Eye Res 13: 885-890. doi: 10.3109/02713689409015091. PubMed: 7720396.

47. Zhang JJ, Jacob TJ, Valverde MA, Hardy SP, Mintenig GM et al. (1994) Tamoxifen blocks chloride channels. A possible mechanism for cataract formation. J Clin Invest 94: 1690-1697. doi:10.1172/JCI117514. PubMed: 7929848.